BRPI0906831A2 - uso de um inibidor de gama-secretase para tratamento de câncer - Google Patents
uso de um inibidor de gama-secretase para tratamento de câncerInfo
- Publication number
- BRPI0906831A2 BRPI0906831A2 BRPI0906831A BRPI0906831A BRPI0906831A2 BR PI0906831 A2 BRPI0906831 A2 BR PI0906831A2 BR PI0906831 A BRPI0906831 A BR PI0906831A BR PI0906831 A BRPI0906831 A BR PI0906831A BR PI0906831 A2 BRPI0906831 A2 BR PI0906831A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- secretase inhibitor
- gamma secretase
- gamma
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2044708P | 2008-01-11 | 2008-01-11 | |
PCT/EP2009/050047 WO2009087130A1 (en) | 2008-01-11 | 2009-01-05 | Use of a gamma-secretase inhibitor for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0906831A2 true BRPI0906831A2 (pt) | 2019-09-24 |
Family
ID=40365425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0906831A BRPI0906831A2 (pt) | 2008-01-11 | 2009-01-05 | uso de um inibidor de gama-secretase para tratamento de câncer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090181944A1 (pt) |
EP (1) | EP2244713A1 (pt) |
JP (3) | JP5612482B2 (pt) |
KR (2) | KR20140007979A (pt) |
CN (1) | CN101909633B (pt) |
AR (1) | AR072442A1 (pt) |
AU (1) | AU2009203776A1 (pt) |
BR (1) | BRPI0906831A2 (pt) |
CA (1) | CA2710913A1 (pt) |
CL (1) | CL2009000040A1 (pt) |
CR (1) | CR11510A (pt) |
IL (1) | IL206361A0 (pt) |
MA (1) | MA33076B1 (pt) |
RU (1) | RU2010133489A (pt) |
TW (1) | TW200936139A (pt) |
WO (1) | WO2009087130A1 (pt) |
ZA (1) | ZA201004859B (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
CA2743436C (en) | 2008-11-24 | 2017-10-31 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
US8309299B2 (en) * | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
WO2012050370A2 (ko) * | 2010-10-15 | 2012-04-19 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
KR101330184B1 (ko) | 2010-10-15 | 2013-11-15 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
US20120114638A1 (en) * | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
US20120225860A1 (en) * | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
AU2013312358B2 (en) | 2012-09-07 | 2018-08-09 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
CN104854097A (zh) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物 |
EP2897944B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
WO2014047374A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
CN104822665A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物 |
EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
EP2897941B1 (en) | 2012-09-21 | 2016-09-07 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
JP2015529250A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | フルオロアルキルジベンゾジアゼピノン化合物 |
EP2981267A1 (en) * | 2013-04-04 | 2016-02-10 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
CA2934250A1 (en) * | 2013-12-17 | 2015-06-25 | Rush University Medical Center | Compositions and methods for treating diabetic nephropathy |
WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
US11370823B2 (en) | 2014-10-29 | 2022-06-28 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
WO2017096233A1 (en) | 2015-12-04 | 2017-06-08 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
AU2017212655B2 (en) | 2016-01-29 | 2024-01-18 | Decibel Therapeutics, Inc. | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
WO2017200762A2 (en) | 2016-05-16 | 2017-11-23 | The General Hospital Corporation | Human airway stem cells in lung epithelial engineering |
ES2904880T3 (es) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 |
JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス, インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
KR102094442B1 (ko) | 2018-06-28 | 2020-03-27 | 성균관대학교산학협력단 | 알쯔하이머성 치매의 예방 또는 치료용 물질 및 이를 포함하는 조성물 |
WO2022067185A1 (en) * | 2020-09-27 | 2022-03-31 | Veru Inc. | Methods of treating prostate cancer with minimal side effects |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6012A (en) * | 1849-01-09 | Lithographing co | ||
KR100838852B1 (ko) * | 2003-09-09 | 2008-06-16 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
US7211573B2 (en) * | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
KR20070108402A (ko) * | 2005-02-15 | 2007-11-09 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 화학요법제와 il-2 및 선택적으로 항-cd20 항체의조합물을 사용하여 임파종을 치료하는 방법 |
EP1888051A2 (en) * | 2005-05-17 | 2008-02-20 | MERCK SHARP & DOHME LTD. | Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer |
EP1996182A4 (en) * | 2006-02-27 | 2009-08-12 | Univ Johns Hopkins | CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS |
-
2009
- 2009-01-05 MA MA33027A patent/MA33076B1/fr unknown
- 2009-01-05 KR KR1020137035150A patent/KR20140007979A/ko not_active Application Discontinuation
- 2009-01-05 AU AU2009203776A patent/AU2009203776A1/en not_active Abandoned
- 2009-01-05 EP EP09700208A patent/EP2244713A1/en not_active Withdrawn
- 2009-01-05 CN CN2009801017331A patent/CN101909633B/zh not_active Expired - Fee Related
- 2009-01-05 JP JP2010541761A patent/JP5612482B2/ja not_active Expired - Fee Related
- 2009-01-05 CA CA2710913A patent/CA2710913A1/en not_active Abandoned
- 2009-01-05 WO PCT/EP2009/050047 patent/WO2009087130A1/en active Application Filing
- 2009-01-05 BR BRPI0906831A patent/BRPI0906831A2/pt not_active IP Right Cessation
- 2009-01-05 KR KR1020107014569A patent/KR20100101624A/ko active Application Filing
- 2009-01-05 RU RU2010133489/15A patent/RU2010133489A/ru unknown
- 2009-01-05 US US12/348,464 patent/US20090181944A1/en not_active Abandoned
- 2009-01-08 TW TW098100518A patent/TW200936139A/zh unknown
- 2009-01-08 AR ARP090100051A patent/AR072442A1/es unknown
- 2009-01-09 CL CL2009000040A patent/CL2009000040A1/es unknown
-
2010
- 2010-06-14 IL IL206361A patent/IL206361A0/en unknown
- 2010-06-17 CR CR11510A patent/CR11510A/es not_active Application Discontinuation
- 2010-07-09 ZA ZA2010/04859A patent/ZA201004859B/en unknown
-
2013
- 2013-07-25 JP JP2013154790A patent/JP2013241443A/ja not_active Ceased
-
2014
- 2014-06-13 JP JP2014122580A patent/JP2014221772A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2710913A1 (en) | 2009-07-16 |
ZA201004859B (en) | 2011-03-30 |
CR11510A (es) | 2010-09-13 |
JP5612482B2 (ja) | 2014-10-22 |
MA33076B1 (fr) | 2012-03-01 |
AU2009203776A1 (en) | 2009-07-16 |
CL2009000040A1 (es) | 2010-02-12 |
WO2009087130A1 (en) | 2009-07-16 |
KR20100101624A (ko) | 2010-09-17 |
AR072442A1 (es) | 2010-09-01 |
KR20140007979A (ko) | 2014-01-20 |
JP2011509273A (ja) | 2011-03-24 |
TW200936139A (en) | 2009-09-01 |
CN101909633A (zh) | 2010-12-08 |
JP2013241443A (ja) | 2013-12-05 |
IL206361A0 (en) | 2010-12-30 |
JP2014221772A (ja) | 2014-11-27 |
US20090181944A1 (en) | 2009-07-16 |
CN101909633B (zh) | 2012-05-30 |
RU2010133489A (ru) | 2012-02-20 |
EP2244713A1 (en) | 2010-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0906831A2 (pt) | uso de um inibidor de gama-secretase para tratamento de câncer | |
BRPI0906186A2 (pt) | composto e uso de um composto | |
BRPI1010937A2 (pt) | composto, uso de um composto, e, método para tratar câncer | |
BRPI0915231A2 (pt) | compostos inibidores de quinase e métodos de uso | |
BRPI0910346A2 (pt) | compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso | |
BR112013025353A2 (pt) | combinações de compostos de inibidores de akt e erlotinibe e métodos de uso | |
BRPI1009333A2 (pt) | inibidores de beta-secretase | |
BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
BRPI1014572A2 (pt) | imidazoprazinas para uso como inibidores de cinase | |
DK2178888T3 (da) | Proteasomhæmmere | |
BRPI0908100A2 (pt) | produto combinação, uso de um composto, e, método de tratar câncer | |
BR112012004281A2 (pt) | uso de metformina tratamento e prevenção de câncer | |
BRPI0717411A2 (pt) | Uso de inibidores de iap | |
BRPI0906444A2 (pt) | Compostos de 4-piridinona e seu uso para câncer | |
BRPI0906352A2 (pt) | Derivado de tiazol e uso do mesmo como inibidores de vap-1 | |
BRPI0915134A2 (pt) | composto, e, uso de um composto | |
BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos | |
BRPI0918688C8 (pt) | composto fluorescente e hidrofílico e uso de um composto fluorescente e hidrofílico | |
BRPI0814256A2 (pt) | Inibidores de tetrahidropiranocromeno gama secretase | |
BR112012005774B8 (pt) | uso de um inibidor de quinase antiangiogênico no tratamento de câncer | |
BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
BRPI1007494A2 (pt) | composto e uso do mesmo | |
BRPI1015367A2 (pt) | imidazotiodiazois para uso como inibidores de cinase | |
BRPI0922344A2 (pt) | inibidores de tfpi e métodos de uso | |
BRPI0814304A2 (pt) | Uso de um composto metálico misto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |